Blake P, Burkart J M, Churchill D N, Daugirdas J, Depner T, Hamburger R J, Hull A R, Korbet S M, Moran J, Nolph K D
University of Western Ontario, London, Canada.
Perit Dial Int. 1996 Sep-Oct;16(5):448-56.
Data from the Canada-U.S.A. (CANUSA) Study have recently confirmed a long-suspected linkage between total clearance and patient survival in peritoneal dialysis (PD). Recognizing that what we have historically accepted as adequate PD simply is not, the Ad Hoc Committee on Peritoneal Dialysis Adequacy met in January, 1996. This committee of invited experts was convened by Baxter Healthcare Corporation to prepare a consensus statement that provides clinical recommendations for achieving clearance guidelines for peritoneal dialysis. Through an analysis of 806 PD patients, the group concluded that adequate clearance delivered with PD can be achieved in almost all patients if the prescription is individualized according to the patient's body surface area, amount of residual renal function, and peritoneal membrane transport characteristics. Use of 2.5 L to 3.0 L fill volumes, the addition of an extra exchange, and giving automated peritoneal dialysis patients a "wet" day are all options to consider when increasing weekly creatinine clearance and KT/V. Rather than specify a single clearance or KT/V target, the recommended clinical practice is to provide the most dialysis that can be delivered to the individual patient, within the constraints of social and clinical circumstances, quality of life, life-style, and cost. The challenge to PD practitioners is to make prescription management an integral part of everyday patient management. This includes assessment of peritoneal membrane permeability, measurement of dialysis and residual renal clearance, and adjustment of the dialysis prescription when indicated.
加拿大-美国(CANUSA)研究的数据最近证实了长期以来人们所怀疑的腹膜透析(PD)中总清除率与患者生存率之间的联系。认识到我们过去一直认为足够的腹膜透析实际上并不够,腹膜透析充分性特设委员会于1996年1月召开会议。该委员会由百特医疗保健公司召集,成员为受邀专家,旨在编写一份共识声明,为实现腹膜透析清除率指南提供临床建议。通过对806例腹膜透析患者的分析,该小组得出结论:如果根据患者的体表面积、残余肾功能和腹膜转运特性进行个体化处方,几乎所有患者都能通过腹膜透析实现足够的清除率。当增加每周肌酐清除率和KT/V时,使用2.5升至3.0升的灌注量、增加一次额外交换以及给自动化腹膜透析患者安排一个“湿”日都是可以考虑的选择。推荐的临床实践不是规定单一的清除率或KT/V目标,而是在社会和临床情况、生活质量、生活方式及成本的限制范围内,为个体患者提供尽可能多的透析。腹膜透析从业者面临的挑战是将处方管理作为日常患者管理的一个组成部分。这包括评估腹膜通透性、测量透析和残余肾清除率,并在必要时调整透析处方。